A Journey Through JAK Inhibitors for the Treatment of Myeloproliferative Diseases.

IF 2.7 3区医学 Q2 HEMATOLOGY

Current Hematologic Malignancy Reports Pub Date : 2023-10-01 Epub Date: 2023-07-03 DOI:10.1007/s11899-023-00702-x

Andrea Duminuco, Elena Torre, Giuseppe A Palumbo, Claire Harrison

{"title":"A Journey Through JAK Inhibitors for the Treatment of Myeloproliferative Diseases.","authors":"Andrea Duminuco, Elena Torre, Giuseppe A Palumbo, Claire Harrison","doi":"10.1007/s11899-023-00702-x","DOIUrl":null,"url":null,"abstract":"Purpose of review: Chronic myeloproliferative neoplasms (MPN) represent a group of diseases characterised by constitutive activation of the JAK/STAT pathway in a clonal myeloid precursor. The therapeutic approach aims to treat the symptom burden (headache, itching, debilitation), splenomegaly, slow down the fibrotic proliferation in the bone marrow and reduce the risk of thrombosis/bleeding whilst avoiding leukaemic transformation.Recent findings: In recent years, the advent of JAK inhibitors (JAKi) has significantly broadened treatment options for these patients. In myelofibrosis, symptom control and splenomegaly reduction can improve quality of life with improved overall survival, not impacting progression into acute leukaemia. Several JAKi are available and used worldwide, and combination approaches are now being explored. In this chapter, we review the approved JAKi, highlighting its strengths, exploring potential guidelines in choosing which one to use and reasoning towards future perspectives, where the combinations of therapies seem to promise the best results.","PeriodicalId":10852,"journal":{"name":"Current Hematologic Malignancy Reports","volume":"18 5","pages":"176-189"},"PeriodicalIF":2.7000,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Hematologic Malignancy Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11899-023-00702-x","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/7/3 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 2

Abstract

Purpose of review: Chronic myeloproliferative neoplasms (MPN) represent a group of diseases characterised by constitutive activation of the JAK/STAT pathway in a clonal myeloid precursor. The therapeutic approach aims to treat the symptom burden (headache, itching, debilitation), splenomegaly, slow down the fibrotic proliferation in the bone marrow and reduce the risk of thrombosis/bleeding whilst avoiding leukaemic transformation.

Recent findings: In recent years, the advent of JAK inhibitors (JAKi) has significantly broadened treatment options for these patients. In myelofibrosis, symptom control and splenomegaly reduction can improve quality of life with improved overall survival, not impacting progression into acute leukaemia. Several JAKi are available and used worldwide, and combination approaches are now being explored. In this chapter, we review the approved JAKi, highlighting its strengths, exploring potential guidelines in choosing which one to use and reasoning towards future perspectives, where the combinations of therapies seem to promise the best results.

Abstract Image

查看原文本刊更多论文

JAK抑制剂治疗骨髓增生性疾病之旅。

综述目的：慢性骨髓增生性肿瘤（MPN）是一组以克隆性骨髓前体中JAK/STAT通路的组成型激活为特征的疾病。该治疗方法旨在治疗症状负担（头痛、瘙痒、虚弱）、脾肿大，减缓骨髓中的纤维化增殖，降低血栓形成/出血的风险，同时避免白血病转化。最近的发现：近年来，JAK抑制剂（JAKi）的出现显著拓宽了这些患者的治疗选择。在骨髓纤维化中，症状控制和脾肿大减轻可以提高生活质量，提高总生存率，而不影响进展为急性白血病。一些JAKi在世界范围内可用和使用，目前正在探索组合方法。在本章中，我们回顾了批准的JAKi，强调了它的优势，探索了选择使用哪种JAKi的潜在指导方针，并对未来的前景进行了推理，在未来，各种疗法的组合似乎有望取得最佳效果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Hematologic Malignancy Reports ONCOLOGY-HEMATOLOGY

CiteScore

6.00

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： his journal intends to provide clear, insightful, balanced contributions by international experts that review the most important, recently published clinical findings related to the diagnosis, treatment, management, and prevention of hematologic malignancy. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as leukemia, lymphoma, myeloma, and T-cell and other lymphoproliferative malignancies. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.